Connected Drug Delivery Devices Market (2nd Edition): Industry Trends and Global Forecasts, till 2035

Connected Drug Delivery Devices Market (2nd Edition): Industry Trends and Global Forecasts, till 2035

The Connected Drug Delivery Devices Market is valued at USD 4.4 billion in 2024 and is projected to grow at a CAGR of 10.1%, during the forecast period till 2035.

Noncompliance with prescribed medications is a prevalent issue in the healthcare industry, contributing to poor health outcomes (including chronic disease progression and high risk of mortality), increased cases of hospitalization and high healthcare costs. Studies reveal that around 66% of the people in the US are prescribed at least one medicine; of these, 50% are not taken by patients as directed by the physicians. The factors contributing to the non-adherence towards medications include patient forgetfulness, perception of associated side effects, difficulty in accessing medications, complicated dosing schedules and lack of access to adequate healthcare services. Notably, poor adherence to medication regimen poses a substantial financial burden on the healthcare system; specifically in the US, it costs around USD 290 billion annually. In order to address this concern, various strategies are being employed, such as simplifying the dosage regimens, offering personalized medication schedules, educating the patients and providing behavioral support.

Connected drug delivery devices turn out to be a significant advancement in this area. These are characterized as advanced medical devices that are designed to improve drug administration and monitoring, using digital technologies. These devices are embedded with advanced features and sensors, and have wireless connectivity capabilities (primarily facilitated through Bluetooth, near field communication, Wi-Fi or cellular networks), enabling convenient connection to mobile applications, digital health platforms and electronic health records. These devices enable real-time collection and transfer of data related to patients medication usage, compliance and overall health status, allowing remote monitoring of patient (to enable timely interventions), analyzing disease patterns (to optimize treatment plans), sharing reminders / alerts to patients (to follow their dosage schedules consistently), encouraging participation of patients in their health management and reducing the overall healthcare expenditures.

It is noteworthy that various add-on sensors are also being developed that are useful in transforming conventional drug delivery devices into advanced ones. With the growing demand for accurate and effective digital health solutions and advancement in technologies (integration with telehealth platforms), the global connected drug delivery devices market is poised to witness steady growth, in the future outlook.

Key Market Segments

Type of Device

• Connected / Smart Wearable Injectors
• Connected / Smart Inhalers
• Connected / Smart Pen Injectors
• Connected / Smart Autoinjectors
• Connected / Smart Needle-free Injection Systems

Mode of Connectivity

• Bluetooth-enabled Devices
• Near Field Communication-enabled Devices
• Cellular-enabled Devices
• Wide Area Network-enabled Devices

Route of Administration

• Parenteral
• Inhalational

Therapeutic Area

• Metabolic Disorders
• Respiratory Disorders
• Autoimmune Disorders
• Other Disorders

Geographical Regions

• North America (US and Canada)
• Europe (UK, Germany, France, Italy, Spain and Rest of Europe)
• Asia-Pacific (China, India, Japan and Rest of the Asia-Pacific)
• Middle East and North Africa (Egypt, Israel, Argentina and the Rest of the Middle East and North Africa)
• Latin America and the Rest of the World (Brazil, Argentina and Other Countries)

Research Coverage:

The market report on Connected Drug Delivery Devices covers the following elements:

• An introduction to medication adherence, highlighting the different digital solutions that enhance a patient’s ability to follow their prescribed dosage regimens. The chapter also includes details about the connected / smart drug delivery systems, their different types (based on type of device and technology used), key features and development processes involved. Further, it outlines the regulatory guidelines governing the development and approval of connected / smart drug delivery systems. Furthermore, the chapter also discusses the various advantages and limitations of these systems, as well as the impact of COVID-19 pandemic on this domain.
• An insightful analysis of the overall connected drug delivery devices market landscape, featuring information on several relevant parameters, such as stage of development (approved / launched and under development), launch year of device, type of integrated device (smart handheld injector, smart wearable injector, smart inhalers, smart pill and others), route of administration (subcutaneous, inhalation, oral, intramuscular, epidural, others), therapeutic area (metabolic disorders, respiratory disorders, neurological disorders, autoimmune disorders, chronic disorders, oncological disorders, cardiovascular disorders, immunological disorders, pain disorders and other disorders), target indication, key features (audio / visual alerts and reminders / notifications), mode of connectivity (Bluetooth, USB, internet connectivity, near field communication), availability of companion mobile application and availability of data storage / cloud platform. In addition, it also encompasses tabulated information on regulatory approvals, geographical reach and drugs compatible with connected / smart drug delivery devices. Further, the chapter includes the list of companies engaged in manufacturing connected drug delivery devices, along with detailed analysis based on various parameters, such as year of establishment, company size (in terms of employee count), location of headquarters and most active players (in terms of the number of integrated connected drug delivery devices manufactured).
• An extensive analysis of the overall market landscape of add-on sensors, featuring insights based on several relevant parameters, such as stage of development (approved / launched and under development), launch year of device, compatible device (handheld injectors, inhalers and others), route of administration (inhalation, subcutaneous, ophthalmic and oral), therapeutic area (respiratory disorder, metabolic disorder, growth disorder and infectious disease), target indication, key features (audio / visual alerts and reminders / notifications), mode of connectivity (Bluetooth, USB, internet connectivity, near field communication), availability of companion mobile application and availability of data storage / cloud platform. It also includes tabulated information on regulatory approvals, geographical reach and drugs that can be delivered using add-on sensors (in combination with conventional drug delivery devices). Further, the chapter presents a list of companies engaged in manufacturing add-on sensors for drug delivery devices, along with detailed analysis based on various parameters, such as year of establishment, company size (in terms of employee count), location of headquarters and most active players (in terms of the number of add-on sensors manufactured).
• An insightful competitiveness analysis of the connected drug delivery devices and add-on sensors, based on the manufacturer strength (in terms of years of establishment and company size) and portfolio strength (in terms of stage of development, route of administration, therapeutic area, key features, mode of connectivity and availability of data storage / cloud platform).
• A comprehensive set of profiles of leading players manufacturing connected drug delivery devices, based in North America, Europe and Asia-Pacific (shortlisted based on the number of connected drug delivery devices / add-on sensors offered), wherein each profile features a brief overview of the company (including information on their year of establishment, location of headquarters, number of employees, leadership team, business segments and contact details), financial information (if available), connected drug delivery devices portfolio, recent developments and an informed future outlook.
• An in-depth analysis of completed and ongoing clinical trials related to connected drug delivery devices, during the time period pre-2011-2020, based on several relevant parameters, such as trial registration year, enrolled patient population, trial phase, trial status, type of device, type of sponsor / collaborator, therapeutic area, study design (type of trial masking, type of intervention model, trial purpose and design allocation), leading industry players (based on number of clinical trials), leading connected / smart drug delivery devices (based on number of clinical trials) and geography.
• An exhaustive list of the partnerships and collaborations, inked between various stakeholders in the connected drug delivery devices market (during the period 2020-2024), which have been analyzed based on several parameters, such as year of partnership, type of partnership, class of device, type of integrated device, compatible device and most active players (in terms of number of partnerships signed). It also provides analysis of the regional distribution of the companies involved in these agreements.
• A comprehensive discussion of the funding and investments raised by connected drug delivery device manufacturers, during the period 2020-2024, based on relevant parameters, such as year of funding, amount invested (USD million), type of funding, class of device, geography, most active players (in terms of number of funding instances and amount raised), and most active investors (in terms of number of funding instances).
• An in-depth value chain analysis featuring a discussion on various steps involved in the development of connected / smart drug delivery devices, including research and development (R&D), product manufacturing and assembly, product distribution, marketing and sales, and post-market surveillance, along with the information on cost requirements across each of the aforementioned stages.
• Detailed case studies on the two most prevalent diseases (namely, asthma and diabetes), featuring a brief description of the disease, its epidemiology, economic burden (imposed due to non-adherence to prescribed treatments), and a summary of the evolution of drug delivery devices and other strategies focused on improving therapy adherence among patients suffering from the indication.
• An informative summary of various guidelines established and issued by major regulatory bodies for the approval of connected drug delivery devices, across different countries / geographical regions.
• A thorough discussion on industry affiliated trends, opportunities and challenges, under a SWOT analysis, which are likely to impact the evolution of connected drug delivery devices market; it includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics.
• A comprehensive assessment of the current market size and opportunity, and future growth potential for the connected drug delivery device manufacturers over the next decade. Based on multiple parameters, likely adoption trends and through primary validations, we have provided informed projections on the market’s evolution, till 2035. The report also provides light on the likely distribution of the current and forecasted opportunity within the connected drug delivery devices market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
• Detailed forecasted estimates of the current and future opportunity within the connected drug delivery devices industry across type of device, such as connected / smart wearable injectors, connected / smart inhalers, connected / smart pen injectors, connected / smart autoinjectors and connected / smart needle free drug delivery devices.
• Detailed forecasted estimates of the current and future opportunity within the connected drug delivery devices market across mode of connectivity, such as Bluetooth-enabled devices, near field communication-enabled devices, cellular-enabled devices and wide area network-enabled devices.
• Detailed forecasted estimates of the current and future opportunity within the market for connected drug delivery devices across route of administration, such as parenteral and inhalational.
• Detailed forecasted estimates of the current and future opportunity within the connected drug delivery devices industry across therapeutic area, such as metabolic disorders, respiratory disorders, autoimmune disorders and other disorders.
• Detailed forecasted estimates of the current and future opportunity within the connected drug delivery devices market across geographical regions, such as North America (US and Canada), Europe (UK, Germany, France, Italy, Spain and Rest of the Europe), Asia-Pacific (China, India, Japan and Rest of the Asia-Pacific), Middle East and North Africa (Egypt, Israel, Saudi Arabia and Rest of the Middle East and North Africa), and Latin America and Rest of the World (Brazil, Argentina and other countries).

Key Benefits of Buying this Report

• The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
• Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
• The report provides stakeholders with a pulse on the Connected Drug Delivery Devices Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Companies Profiled

• Bigfoot Biomedical
• BIOCORP
• Eitan Medical
• E3D Elcam Drug Delivery Device
• EoFlow
• Gerresheimer
• Insulet
• Medtronic
• Medtrum
• Nemera
• Phillips-Medisize
• Roche
• Sonceboz
• SOOIL Development
• Tandem Diabetes Care
• West Pharmaceutical Services
• Ypsomed